Brief: Oxigene says receives European orphan drug designation for CA4P
25/03/2016 12:30
March 25 (Reuters) - Oxigene Inc OXGN.O :
* European commission has granted orphan drug designation to
CA4P for treatment of gastro-entero-pancreatic neuroendocrine
tumors
* Oxigene receives European orphan drug designation for ca4p
to treat neuroendocrine tumors
Source text for Eikon: ID:nGNXMQFOBa
Further company coverage: OXGN.O
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas